AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30882524
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (8 mL/h of 0.1% ropivacaine with 2 µg/mL fentanyl)
Trial: 29947142
Drug: Cognitive games
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive games group (experimental group) - card and board games training executive functions, 30-min training session twice a week for six weeks.
Trial: 28513426
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (pregabalin 150-mg capsule)
Trial: 28513426
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (pregabalin 150-mg capsule)
Trial: 28513426
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and Reference products (pregabalin 150-mg capsule)
Trial: 22094540
Drug: Docetaxel/gemcitabine (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/gemcitabine (arm A: docetaxel 75 mg/m(2) on day 1, gemcitabine 1,000 mg/m(2) on days 1 and 8)
Trial: 22094540
Drug: Docetaxel/capecitabine (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/capecitabine (arm B: docetaxel 75 mg/m(2) on day 1, capecitabine 1,250 mg/m(2) twice daily on days 1-14)
Trial: 12877614
Drug: Endovascular brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular brachytherapy (EVBT) with high-dose-rate (192)Ir irradiation (12 Gy for a reference vessel radius of 3 mm and a 2-mm reference depth)
Trial: 11774060
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E supplementation (500 or 1000 mg of Vitamin C and 500 or 1000 IU of Vitamin E)
Trial: 8126620
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (5 g/kg/day)
Trial: 8126620
Drug: Standard-protein diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-protein diet (2.5 g/kg/day)
Trial: 239281
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of alcohol in smokers
Trial: 239281
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low dose of alcohol and tobacco in smokers
Trial: 239281
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol in nonsmokers
Trial: 239281
Drug: Smoking dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking dose of nicotine with low levels of alcohol in smokers
Trial: 31545510
Drug: Mannitol in
RxNorm normalized name: mannitol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol in cardiopulmonary bypass prime solution
Trial: 31439215
Drug: Ezetimibe added
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe added to statin therapy
Trial: 26261033
Drug: SPC5001 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPC5001 (5 mg kg(‐1))
Trial: 9403477
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (INR 3.0‐4.5)
Trial: 9403477
Drug: Aspirin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30 mg daily)
Trial: 27803391
Drug: Desmoteplase (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmoteplase (90 μg/kg)
Trial: 22396085
Drug: Methadone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (mean dose at delivery = 63.89 mg)
Trial: 22396085
Drug: Buprenorphine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (mean dose at delivery = 14.05 mg)
Trial: 19249432
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg orally twice a day before and on the day of coronary catheterization (n = 106)
Trial: 19249432
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 3 g and 2 g orally before, and 2 g twice after coronary catheterization with a 12-hour interval (n = 106)
Trial: 19249432
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) in patients with high dose of dye
Trial: 19249432
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid in patients with high dose of dye
Trial: 11573660
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with remifentanil/propofol
Trial: 27922194
Drug: Pregabalin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (200 mg)
Trial: 21454913
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine polacrilex chewing gum
Trial: 14763919
Drug: Insulin-stimulated glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated glucose uptake (ISGU) in FDR
Trial: 14763919
Drug: Insulin-stimulated glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated glucose uptake (ISGU) in controls
Trial: 26255511
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) intervention with stimulation of dense-disperse wave (10 Hz/50 Hz) at Tianshu (ST 25) and Zusanli (ST 36), 0.1 to 1.0 mA, once daily for 5 times a week for 2 weeks, then 2 times a week for 2 weeks.
Trial: 24015975
Drug: Ti (titanium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ti (titanium) 4.1 mm diameter implants
Trial: 24015975
Drug: TiZr (titanium-zirconium)
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiZr (titanium-zirconium) 3.3 mm diameter implants
Trial: 24015975
Drug: Both Ti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Ti and TiZr implants
Trial: 21677073
Drug: Multi-micronutrient beverage
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-micronutrient beverage (250 mL/d including vitamin A, iron, and zinc)
Trial: 19699832
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted educational lessons based on the Medicine Wheel Model for Nutrition (6 lessons over 6 months)
Trial: 16125417
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Motor Training and Action Observation (MT + AO)
Trial: 19780243
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies)
Trial: 9932083
Drug: Irinotecan (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (350 mg/m2 administered over 90 minutes every 3 weeks)
Trial: 3063534
Drug: Rolipram 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolipram 0.50 mg orally t.i.d. for the first three days, then 0.75 mg orally t.i.d. until day 28
Trial: 3063534
Drug: Desipramine 25
RxNorm normalized name: desipramine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 25 mg orally t.i.d. for the first three days, then 50 mg orally t.i.d. until day 28
Trial: 31347193
Drug: High-energy subgroup
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy subgroup (n = 14, mean 599.9 ± 136.5 J/ml)
Trial: 31347193
Drug: Low-energy subgroup
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy subgroup (n = 7, mean 240.2 ± 74.6 J/ml)
Trial: 30818339
Drug: Maternal antiparasitic
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maternal antiparasitic therapy during pregnancy
Trial: 30818339
Drug: 10-valent S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-valent S. pneumoniae conjugate vaccine and pentavalent vaccine
Trial: 29634701
Drug: Tacrolimus (0.03%)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.03%) eye ointment BD
Trial: 26492775
Drug: Heparin, propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin, propranolol with monopril and PCI
Trial: 22710021
Drug: Low-dose statin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose statin plus ezetimibe
Trial: 19382492
Drug: CMC gel
RxNorm normalized name: CMC 001
DrugBank: CMC 001 (DB05353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMC gel
Trial: 14980279
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids used early (<2 wk)
Trial: 14980279
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids used late (>2 wk)
Trial: 3120436
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg nitroglycerin
Trial: 30614468
Drug: Letrozole after
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole after aromatase inhibitor-based therapy
Trial: 26194634
Drug: Corneal cross-linking
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal cross-linking treatment (15 eyes)
Trial: 22963506
Drug: Spironolactone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5 mg and 25 mg)
Trial: 19558610
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg twice daily) in statin users (n = 22)
Trial: 15636668
Drug: Tolterodine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine combined with an educational intervention (printed information and explanation about OAB, medication use, and behavioral treatments)
Trial: 9404828
Drug: Heparin-induced extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-induced extracorporeal low-density lipoprotein (LDL) precipitation (HELP)
Trial: 3465581
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg/day
Trial: 10624252
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on hypnotic medication
Trial: 10624252
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not on hypnotic medication
Trial: 2162239
Drug: Etoposide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (120 mg/m2, days 1‐3)
Trial: 2162239
Drug: Etoposide plus
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide plus high-dose cisplatin (60 mg/m2, days 1‐2)
Trial: 2162239
Drug: Etoposide plus
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide plus high-dose cisplatin
Trial: 469108
Drug: Caffeine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (low dose equivalent to one cup of coffee)
Trial: 469108
Drug: Caffeine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (high dose equivalent to three cups of coffee)
Trial: 23168228
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (SQ group): PPI + amoxicillin for 5 days followed by PPI + clarithromycin + metronidazole for 5 days
Trial: 23168228
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (AM group): PPI + amoxicillin + metronidazole for 7 days
Trial: 23168228
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (AC group): PPI + amoxicillin + clarithromycin for 7 days
Trial: 23168228
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (SQ group)
Trial: 23168228
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (AM group)
Trial: 23168228
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (AC group)
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for alliance
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for non-positive learning statements received from counselor
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for participation variables
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for self-disclosures about the past
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for group cohesion
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for degree of participation of each group member
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for positive feedback
Trial: 21409739
Drug: Videotaped group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped group drug counseling sessions rated for negative feedback
Trial: 10741082
Drug: TIVA (Total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (Total Intravenous Anesthesia) using a mixture of propofol (45 ml of 1%) and alfentanil (2,500 micrograms)
Trial: 2865615
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate patches
Trial: 12433647
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of puerarin injection
Trial: 12433647
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of anisodamine
Trial: 8607174
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily (n=77)
Trial: 8607174
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous steroids (IVS) 5 mg/kg for 5 days (n=73)
Trial: 8607174
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous steroids (IVS)
Trial: 1945993
Drug: Fenoterol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.25 mg/kg)
Trial: 30607677
Drug: Topical FDX104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical FDX104 4% foam applied twice daily for 5 weeks
Trial: 30607677
Drug: Vehicle foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle foam (placebo) applied twice daily for 5 weeks
Trial: 30607677
Drug: Topical FDX104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical FDX104 4% foam
Trial: 21175277
Drug: Software recommendations
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Software recommendations for insulin dosage adjustments
Trial: 21175277
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy titrated every 1-4 weeks
Trial: 18300511
Drug: Capsule YD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule YD
Trial: 11497396
Drug: lenograstim (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenograstim (2 microg/kg daily, s.c.)
Trial: 9613651
Drug: Tetravalent rhesus
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent rhesus rotavirus vaccine (RV‐TV)
Trial: 9613651
Drug: Dose 1
RxNorm normalized name: Aldose 1-epimerase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 of RV‐TV
Trial: 9613651
Drug: Dose 2
RxNorm normalized name: Fluzone High-Dose 2011-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2 of RV‐TV
Trial: 9613651
Drug: Dose 3
RxNorm normalized name: Dial-A-Dose 30mL Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 3 of RV‐TV
Trial: 9613651
Drug: Plaque purification
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plaque purification and serotyping after Dose 1
Trial: 9613651
Drug: Plaque purification
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plaque purification and serotyping after Dose 2
Trial: 9613651
Drug: Plaque purification
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plaque purification and serotyping after Dose 3
Trial: 8021329
Drug: Fixed-dose transdermal
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose transdermal nicotine (21 or 22 mg/day for 6 weeks)
Trial: 8021329
Drug: Tapered-dose transdermal
RxNorm normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapered-dose transdermal nicotine (21 or 22 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks)
Trial: 8021329
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 mg TID for 7 days, then 10 mg TID for 21 days)
Trial: 2563951
Drug: Coated mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coated mesalazine (Mesasal) 1.5 g daily
Trial: 2563951
Drug: Sulphasalazine 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine 3.0 g daily
Trial: 31492505
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg once daily) plus a P2Y12 inhibitor for 12 months
Trial: 31492505
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) in combination with a P2Y12 inhibitor and aspirin (100 mg once daily, for 1-12 months)
Trial: 24787143
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg/d
Trial: 24787143
Drug: Vortioxetine 20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 20 mg/d
Trial: 20414864
Drug: Self-report of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-report of recent-onset rectal bleeding
Trial: 16055161
Drug: A‐linked proanthocyanidins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐linked proanthocyanidins from cranberry juice cocktail at 60 microg/ml
Trial: 16055161
Drug: B‐type proanthocyanidins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐type proanthocyanidins from grape at 1200 microg/ml
Trial: 11736673
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg kg(‐1) with fentanyl 100 microg)
Trial: 9225827
Drug: Ethanol (0.52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.52 g/kg during 2 hours and 0.3 g/kg during 3 hours)
Trial: 9225827
Drug: Ethanol (0.69
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.69 g/kg during 2 hours and 0.3 g/kg during 3 hours)
Trial: 9225827
Drug: Ethanol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (higher dose)
Trial: 2585237
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered immune globulin (IVIG)
Trial: 20023357
Drug: Hyaluronan (Hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan (Hylan G‐F 20)
Trial: 16911176
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tobacco and drug education curriculum)
Trial: 16209203
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication (antibiotic, indomethacin, alpha1 receptor blocker and Chinese traditional medicine)